Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine ( PNEUMOSIL® )

• DOI: 10.1080/21645515.2021.1874219
• Publication Date: 2021-02-24T21:27:52Z
• Authors: Mark R. Alderson; Vistasp Sethna; Lauren C. Newhouse; Steve Lamola; Rajeev Dhere
• Keywords: Pneumococcal Conjugate Vaccine

Pneumococcal conjugate vaccines (PCVs) have proven to be the best way prevent severe childhood pneumococcal disease but until recently been difficult for many countries afford sustainably. In 2008, Serum Institute of India, Pvt. Ltd. and PATH entered into a collaboration, funded in part by Bill & Melinda Gates Foundation, respond this problem developing PCV designed affordable, accessible, protective against serotypes causing most morbidity mortality low- middle-income countries. The resulting 10-valent (PNEUMOSIL®) received World Health Organization prequalification December 2019 – making it just third certified as an option Gavi, Vaccine Alliance-eligible is being made available at Gavi price US$2/dose. task state-of-the-art, yet lower-priced, required public-private collaboration across geographies yielded variety successes learnings useful vaccine development field. Key among were factors related manufacturing strategy optimization, serotype selection, flexibility, early risk detection mitigation, partner trust continuity similar-class products, complementary business philosophies, clarity purpose.